Akso Health Group

What they do

The filing identifies the company as Akso Health Group, listed on the Nasdaq Capital Market under the symbol AHG, with ADSs each representing three Class A ordinary shares. Its principal executive offices are in the Qingdao Pilot Free Trade Zone, China, and the report references entities including Hexin Digital, Hexin E-commerce, Hexin Jinke and Akso Online MediTech, as well as the Xiaobai Maimai application. The excerpted material includes e-commerce platform-related defined terms such as GMV and "Platforms," which it describes as e-commerce platforms that Hexin Digital cooperates with.

Revenue drivers

• E-commerce platform cooperation (Hexin Digital) — The filing's defined terms refer to "Platforms" as the e-commerce platforms that Hexin Digital cooperates with, and define GMV as the value of confirmed orders on "our platform," indicating this is a platform-based revenue model, but no segment revenue figure or percentage of total revenue is provided in the excerpt.
• Xiaobai Maimai application — The introduction defines "App" and "Xiaobai Maimai" as the Xiaobai Maimai application, indicating an application product line within the business, but no revenue contribution, user count or pricing detail is given in the excerpt.
• Auto leasing (Kuaishangche Automobile Leasing) — The defined-terms section names Kuaishangche Automobile Leasing Co., Ltd., indicating an automobile leasing entity within the group, but the excerpt provides no revenue, fleet size or margin data for it.
• Health-related entity (Akso Online MediTech) — Akso Online MediTech Co., LTD. is named among the company's entities, aligning with the "Health Group" name, but the excerpt contains no description of its products, revenue or scale.

Recent performance

Fiscal 2026, ended March 31, 2026, produced revenue of $13.8 million, down from $14.8 million in fiscal 2025. Net loss was $18.7 million in fiscal 2026, narrower than the $135.0 million loss in fiscal 2025 but far larger than the $1.4 million loss in fiscal 2023. Diluted EPS went from $0.16 in fiscal 2025 to $0.01 in fiscal 2026. Operating cash flow was negative $12.8 million in fiscal 2026, reversing positive $1.2 million in fiscal 2025. At March 31, 2026, total assets were $189.6 million, total liabilities $8.7 million, shareholder equity $180.9 million, and cash and equivalents $170,572.

Strategy

The excerpted portions of the filing do not describe a standalone strategy section, so direction must be inferred from the entities named and the report's structure. The defined terms show a structure that includes e-commerce platform cooperation via Hexin Digital, the Xiaobai Maimai application, automobile leasing via Kuaishangche, and Akso Online MediTech, alongside references to former variable interest entities Hexin Jiuding, Wusu Company and Hexin Digital. No stated investment amounts, acquisition plans, product roadmaps or capital allocation targets appear in the excerpt. The balance sheet ends the period with $180.9 million of shareholder equity against $8.7 million of liabilities and only $170,572 of cash.

Risks

• Persistent losses — The company reported net losses in every year shown from fiscal 2022 through fiscal 2026, including $18.7 million in fiscal 2026.
• Very low cash against large equity base — Cash and equivalents were only $170,572 at March 31, 2026, against $189.6 million of total assets and $180.9 million of shareholder equity.
• Negative operating cash flow — Fiscal 2026 operating cash flow was negative $12.8 million, reversing the positive $1.2 million generated in fiscal 2025.
• Revenue concentration in defined but undisclosed lines — The report describes platform cooperation, an application, auto leasing and a medi-tech entity, but the excerpt provides no segment-level revenue figures, leaving the source of the $13.8 million unclear.

Outlook

The excerpt provided does not include management's forward-looking outlook narrative, guidance or specific targets. What it does show is a fiscal 2026 with lower revenue, a net loss, negative operating cash flow and minimal cash on hand at year-end. No future revenue, margin, cash flow or investment figures appear in the material shown, so no quantitative outlook can be presented from these excerpts.